|
166 |
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges |
Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm JD, Smith R, Teo K, Xavier D |
Eur Heart J |
2014 |
|
167 |
Clonidine in patients undergoing noncardiac surgery |
Devereaux PJ, Sigamani A, Xavier D, Yusuf S, et al |
N Engl J Med |
2014 |
|
168 |
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial |
Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L |
Eur Heart J |
2014 |
|
169 |
Aspirin in patients undergoing noncardiac surgery |
Devereaux PJ, Sigamani A, Xavier D, Yusuf S, et al |
N Engl J Med |
2014 |
|
170 |
Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry |
Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, Zhu J, Jansky P, Sigamani A, Morillo CA, Liu L, Damasceno A, Grinvalds A, Nakamya J, Reilly PA, Keltai K, Van Gelder IC, Yusufali AH, Watanabe E, Wallentin L, Connolly SJ, Yusuf S |
Circulation |
2014 |
|
171 |
Rationale and design of the Primary pREvention strategies at the community level to Promote Adherence of treatments to pREvent cardiovascular diseases trial number (CTRI/2012/09/002981) |
Fathima FN, Joshi R, Agrawal T, Hegde S, Xavier D, Misquith D, Chidambaram N, Kalantri SP, Chow C, Islam S, Devereaux PJ, Gupta R, Pais P, Yusuf S |
Am Heart J |
2013 |
|
172 |
Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial |
Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. |
Am Heart J |
2013 |
|
173 |
New evidence for gender disparities in cardiac interventions: ‘CREATE’-ing some clarity. |
Sigamani A, Kamath D, Xavier D, Pais P. |
Future Medicine |
2013 |
|
174 |
Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation |
Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. |
Stroke |
2013 |
|
175 |
Effect of B Vitamins and Lowering Homocysteine on Cognitive Impairment in Patients With Previous Stroke or Transient Ischemic Attack: A Prespecified Secondary Analysis of a Randomized, Placebo-Controlled Trial and Meta-Analysis. |
Hankey GJ, Ford AH, Yi Q, Eikelboom JW, Lees KR, Chen C, Xavier D, Navarro JC, Ranawaka UK, Uddin W, Ricci S, Gommans J, Schmidt R, Almeida OP, van Bockxmeer FM; on Behalf of the VITATOPS Trial Study Group. |
Stroke |
2013 |
|
176 |
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study |
Connolly SJ, Wallentin L, Ezekowitz MD, Pais P, Xavier D, Wang SQ, Yusuf S, et al |
Circulation |
2013 |
|
177 |
P2Y12 inhibitors in acute coronary syndromes: which and when? |
Pais P |
Natl Med J India |
2013 |
|
178 |
The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation Clinical Perspective. |
Lars Wallentin, Renato D. Lopes, Michael Hanna, Lain Thomas, Anne Hellkamp, Sunil Nepal, *Denis Xavier* et al |
Circulation |
2013 |
|
179 |
Polypill Is an Important Strategy for the Prevention of Cardiovascular Disease Risk |
*Denis Xavier*, Alben Sigamani, *Deepak Y. Kamath*, *Prem Pais* |
Journal of Clinical and Preventive Cardiology |
2012 |
|
180 |
Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases |
Yusuf S, *Pais P*, Sigamani A, *Xavier D*, Afzal R, Gao P, Teo KK |
Circ Cardiovasc Qual Outcomes |
2012 |